KPC Pharmaceuticals Inc Asset Resilience Ratio
KPC Pharmaceuticals Inc asset resilience ratio. KPC Pharmaceuticals Inc (600422) has an Asset Resilience Ratio of 7.65% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can KPC Pharmaceuticals Inc fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of KPC Pharmaceuticals Inc (2004–2025)
Asset resilience ratio of KPC Pharmaceuticals Inc from 2004 to 2025. This chart shows how KPC Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Read KPC Pharmaceuticals Inc debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down KPC Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see KPC Pharmaceuticals Inc total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥839.72 Million | 7.65% |
| Total Liquid Assets | CN¥839.72 Million | 7.65% |
Asset Resilience Insights
- Limited Liquidity: KPC Pharmaceuticals Inc maintains only 7.65% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
KPC Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare KPC Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Porton Fine Chemicals Ltd
SHE:300363 |
Drug Manufacturers - Specialty & Generic | 6.85% |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA |
Drug Manufacturers - Specialty & Generic | 1.26% |
KPC Pharmaceuticals Inc Asset Resilience Ratio by Year (2004–2025)
KPC Pharmaceuticals Inc asset resilience ratio by year from 2004 to 2025. The table below shows the annual Asset Resilience Ratio data for KPC Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 9.42% | CN¥1.11 Billion ≈ $162.28 Million |
CN¥11.77 Billion ≈ $1.72 Billion |
+5.68pp |
| 2024-12-31 | 3.74% | CN¥471.28 Million ≈ $68.96 Million |
CN¥12.61 Billion ≈ $1.85 Billion |
-1.17pp |
| 2023-12-31 | 4.91% | CN¥603.80 Million ≈ $88.35 Million |
CN¥12.30 Billion ≈ $1.80 Billion |
+1.52pp |
| 2022-12-31 | 3.39% | CN¥319.40 Million ≈ $46.74 Million |
CN¥9.43 Billion ≈ $1.38 Billion |
+1.58pp |
| 2021-12-31 | 1.80% | CN¥160.50 Million ≈ $23.49 Million |
CN¥8.89 Billion ≈ $1.30 Billion |
-2.32pp |
| 2020-12-31 | 4.12% | CN¥334.76 Million ≈ $48.99 Million |
CN¥8.12 Billion ≈ $1.19 Billion |
+1.28pp |
| 2019-12-31 | 2.84% | CN¥210.90 Million ≈ $30.86 Million |
CN¥7.43 Billion ≈ $1.09 Billion |
+1.30pp |
| 2018-12-31 | 1.54% | CN¥106.00 Million ≈ $15.51 Million |
CN¥6.89 Billion ≈ $1.01 Billion |
-8.95pp |
| 2017-12-31 | 10.49% | CN¥665.00 Million ≈ $97.31 Million |
CN¥6.34 Billion ≈ $927.47 Million |
-1.06pp |
| 2016-12-31 | 11.55% | CN¥624.00 Million ≈ $91.31 Million |
CN¥5.40 Billion ≈ $790.52 Million |
-3.22pp |
| 2015-12-31 | 14.77% | CN¥730.80 Million ≈ $106.94 Million |
CN¥4.95 Billion ≈ $724.09 Million |
+11.13pp |
| 2014-12-31 | 3.64% | CN¥110.00 Million ≈ $16.10 Million |
CN¥3.02 Billion ≈ $442.52 Million |
+3.59pp |
| 2004-12-31 | 0.04% | CN¥500.00K ≈ $73.17K |
CN¥1.17 Billion ≈ $171.49 Million |
-- |
About KPC Pharmaceuticals Inc
KPC Pharmaceuticals,Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs and natural drugs in the People's Republic of China and internationally. It offers artemisia annua series, panax notoginseng, gastrodia, artemether, comether tablets, specialty herbal products, classic prescription for bones and joint, ant… Read more